Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aurobindo buys Europe operations from Apotex

Executive Summary

Aurobindo is set to expand its European footprint, “particularly in the generics market of Eastern Europe”, by signing a definitive agreement to acquire for 74 million (US$87 million) in cash Apotex’ businesses in five countries: Belgium, the Czech Republic, the Netherlands, Poland and Spain. Slated to close in the next three-to-six months, the acquisition is subject to clearance by Dutch and Polish competition authorities. Apotex intends to “focus its resources on the Americas, where strong demand for its portfolio continues”.

You may also be interested in...



Aurobindo Integrates Apotex And Prepares For Sandoz

Aurobindo believes it has “substantially addressed” all requirements for an FTC go-ahead for its acquisition of Sandoz’s US dermatology and generic oral solids businesses. The integration of the acquired Apotex business in Europe is also shaping up.

Apotex Mystery: Why Has Accord BioPharma Taken Its Place In US Biosimilar Pegfilgrastim Litigation?

Court grants request to substitute Accord BioPharma for Apotex in Amgen infringement suit. Apotex says it has no plans to exit the biosimilar business.

Apotex Mystery: Why Has Accord BioPharma Taken Its Place In Pegfilgrastim Biosimilar Litigation?

Court grants request to substitute Accord BioPharma for Apotex in Amgen infringement suit. Apotex says it has no plans to exit the biosimilar business.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

GB000962

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel